



Evolution of Multidrug Resistance in *Plasmodium falciparum*: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion

 Mallika Imwong,^{a,b} Kanokon Suwannasin,^b Suttipat Srisutham,^c Ranitha Vongprommek,^d Cholrawee Promnarate,^d Aungkana Saejeng,^e  Aung Pyae Phyo,^f Stephane Proux,^g Tiengkham Pongvongsa,^h Nguon Chea,ⁱ Olivo Miotto,^{b,j,k} Rupam Tripura,^{b,k} Chau Nguyen Hoang,^l Lek Dysoley,ⁱ Nghia Ho Dang Trung,^l Thomas J. Peto,^{b,k} James J. Callery,^b Rob W. van der Pluijm,^b Chanaki Amaratunga,^{b,k} Mavuto Mukaka,^{b,k} Lorenz von Seidlein,^{b,k} Mayfong Mayxay,^{k,m,n} Nguyen Thanh Thuy-Nhien,^l Paul N. Newton,^k Nicholas P. J. Day,^{b,k} Elizabeth A. Ashley,^{k,n} Francois H. Nosten,^{g,k} Frank M. Smithuis,^{f,k} Mehul Dhorda,^{b,c,k} Nicholas J. White,^{b,k} Arjen M. Dondorp^{b,k}

^aDepartment of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

^bMahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

^cDepartment of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand

^dWorldwide Antimalarial Resistance Network, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

^eDivision of Vector-Borne Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand

^fMyanmar Oxford Clinical Research Unit, Yangon, Myanmar

^gShoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand

^hSavannakhet Provincial Health Department, Savannakhet, Lao People's Democratic Republic

ⁱNational Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia

^jWellcome Sanger Institute, Hinxton, United Kingdom

^kCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

^lOxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

^mInstitute of Research and Education Development, University of Health Sciences, Ministry of Health, Vientiane, Lao People's Democratic Republic

ⁿLao–Oxford–Mahosot Hospital–Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic

ABSTRACT Increasing resistance in *Plasmodium falciparum* to artemisinins and their artemisinin combination therapy (ACT) partner drugs jeopardizes effective antimalarial treatment. Resistance is worst in the Greater Mekong subregion. Monitoring genetic markers of resistance can help to guide antimalarial therapy. Markers of resistance to artemisinins (*PfKelch* mutations), mefloquine (amplification of *P. falciparum* multidrug resistance-1 [*PfMDR1*]), and piperazine (*PfPlasmepsin2/3* amplification and specific *P. falciparum* chloroquine resistance transporter [*PfCRT*] mutations) were assessed in 6,722 *P. falciparum* samples from Vietnam, Lao People's Democratic Republic (PDR), Cambodia, Thailand, and Myanmar between 2007 and 2019. Against a high background prevalence of *PfKelch* mutations, *PfMDR1* and *PfPlasmepsin2/3* amplification closely followed regional drug pressures over time. *PfPlasmepsin2/3* amplification preceded piperazine resistance-associated *PfCRT* mutations in Cambodia and reached a peak prevalence of 23/28 (82%) in 2015. This declined to 57/156 (38%) after first-line treatment was changed from dihydroartemisinin-piperazine to artesunate-mefloquine (ASMQ) between 2014 and 2017. The frequency of *PfMDR1* amplification increased from 0/293 (0%) between 2012 and 2017 to 12/156 (8%) in 2019. Amplification of *PfMDR1* and *PfPlasmepsin2/3* in the same parasites was extremely rare (4/6,722 [0.06%]) and was dispersed over time. The mechanisms conferring mefloquine and piperazine resistance may be counterbalancing. This supports the development of ASMQ plus piperazine as a triple artemisinin combination therapy.

KEYWORDS *Plasmodium falciparum*, genetic resistance markers, Greater Mekong subregion

Copyright © 2021 Imwong et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Mallika Imwong, mallika.imwong@mahidol.ac.th.

Received 8 June 2021

Returned for modification 26 August 2021

Accepted 7 September 2021

Accepted manuscript posted online

13 September 2021

Published 17 November 2021

Early diagnosis and treatment, together with vector control, comprise the cornerstone of effective malaria control. Effective early treatment of *Plasmodium falciparum* infections prevents the progression of the disease to severe malaria, which still takes >400,000 lives every year (1). The first-line treatment of uncomplicated falciparum malaria in all countries where malaria is endemic is artemisinin combination therapy (ACT). New compounds are not expected to reach the market before 2026 (2). It is therefore of great concern to regional and global malaria elimination initiatives that artemisinin-resistant *P. falciparum* has emerged and spread in the Greater Mekong subregion (GMS) and, more recently, has emerged independently in Guyana, Papua New Guinea, Ethiopia, and Uganda, and particularly in Rwanda, where its prevalence has increased over recent years (3, 4). In infections with artemisinin-resistant *P. falciparum*, the malaria parasites are still cleared after ACT treatment, but because of the loss of ring-stage susceptibility, parasite killing is reduced and clearance is slower. As a result, the artemisinin component of the ACT contributes less to the antimalarial effect, and efficacy becomes more dependent on the partner drug. Currently, six ACTs are recommended: artesunate-sulfadoxine-pyrimethamine, artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), artesunate-mefloquine (ASMQ), dihydroartemisinin-piperaquine (DHA-PPQ), and, most recently, artesunate-pyronaridine. When susceptibility to the partner drug declines, ACT efficacy drops significantly, and the proportion of recrudescence infections increases. This has been the pattern observed over the past decade in the GMS, where all six recommended artemisinin-based combination therapies have shown reduced efficacy at some point in time (5).

Increasingly, molecular genetic markers for antimalarial drug resistance have been identified, an advance that facilitates the monitoring of the emergence and spread of resistance. Currently, reliable molecular markers are available for *P. falciparum* resistance to artemisinins (mutations in the propeller region of *PfKelch*), sulfadoxine-pyrimethamine (mutations in the dihydrofolate reductase [*PfDHFR*] and dihydropteroate synthase [*PfDHPS*] genes), mefloquine (MQ) (amplification of the multidrug resistance-1 gene [*PfMDR1*]), and piperaquine (amplification of *PfPlasmepsin2/3* and specific mutations in the *P. falciparum* chloroquine resistance transporter gene [*PfCRT*]). Molecular markers accounting for the majority of the variance in susceptibility for the other partner drugs—lumefantrine, amodiaquine, and pyronaridine—are not well established. For some of the drugs, molecular markers can also monitor the evolution of increasing levels of resistance. For sulfadoxine-pyrimethamine, the sequential accumulation of mutations in DHPS and DHFR confer increasing levels of resistance against the two synergistic components (6, 7).

We describe here the evolution of markers of antimalarial drug resistance over time, and the observed combinations of antimalarial resistance markers, in a large set of *P. falciparum* samples obtained from the GMS countries, Vietnam, Lao People's Democratic Republic (PDR), Cambodia, Thailand, and Myanmar, from 2007 to 2019. These observations provide additional insight into the development of mefloquine and piperaquine resistance in the region, and they show the very low prevalence of concomitant markers of resistance to both mefloquine and piperaquine. This has a direct impact on strategies for drug combinations and deployment.

RESULTS

***PfPlasmepsin2/3* and *PfMDR1* gene amplification and *PfKelch* mutations.** *PfPlasmepsin2/3* and *PfMDR1* copy numbers were assessed in 6,722 *P. falciparum* samples from the Greater Mekong subregion—Cambodia ($n = 649$), Laos ($n = 1,332$), Thailand ($n = 666$), Myanmar ($n = 3,925$), and Vietnam ($n = 150$)—between 2007 and 2019. *PfKelch* genotyping was performed for 3,848 of these samples; the remainder had insufficient parasite DNA left after the copy number assessments. Multiple copy numbers of *PfPlasmepsin2/3* were observed in 571 out of 6,722 (8.5%) samples, most of which (519/2,293 [22.6%]) were from the eastern GMS (Vietnam, Lao PDR, Cambodia, northeastern Thailand). The prevalence of multiple copy numbers was substantially lower in the




FIG 1 Changes in the frequencies of amplification of the *PfPlasmepsin2/3* and *PfMDR1* genes and in the frequency of novel piperazine resistance-related *PfCRT* mutations during 2007–2019 in Cambodia. Error bars indicate 95% confidence intervals.

western GMS (Myanmar and western Thailand): 52/4,429 (1.2%) ($P = 0.00001$). Amplification of the *PfMDR1* gene was observed in 321 of 6,722 (4.8%) samples, of which 78/2,293 (3.4%) were from the eastern GMS. Mutations in the propeller region of *PfKelch*, after amino acid position 440, were found in 2,116 of 3,848 (55.0%) samples, of which 555/761 (72.9%) were from the eastern GMS. In the eastern GMS, 432 of 555 *PfKelch* mutants (76.2%) carried the C580Y mutation. In Cambodia between 2007 and 2017, 68 of the 69 parasites with *PfPlasmepsin2/3* amplified (99%) also carried a *PfKelch* propeller region mutation; after the switch to ASMQ as the first-line treatment, this proportion decreased to 61/88 (69%) (Fig. 1).

The prevalence of *PfMDR1* and *PfPlasmepsin2/3* amplification in each country over time was associated with the concurrent first-line antimalarial drug treatment in those countries. In Myanmar, where the first-line therapy is AL, the prevalence of *PfMDR1* (144/3,925 [3.7%]) and *PfPlasmepsin2/3* (50/3,925 [1.3%]) amplification remained low. In Cambodia, the prevalence of *PfMDR1* amplification during the period of first-line treatment with ASMQ reached 16/85 (19%) (Fig. 1), but parasites with *PfMDR1* amplified disappeared after ASMQ was replaced with DHA-PPQ. After the deployment of DHA-PPQ, the prevalence of parasites with *PfPlasmepsin2/3* amplified increased to 23/28 (82%) in 2015. After the slow transition back to ASMQ, starting in 2014, this proportion declined to 57/156 (37%) in 2019. The prevalence of parasites carrying multiple copy numbers of *PfMDR1* increased from 0/293 (0%) between 2012 and 2017 but after full redeployment of ASMQ in 2017 was back to 12/156 (8%) in 2019.

By use of the conventional cutoff of 1.5 to denote gene amplification, parasites with concomitant amplification of *PfPlasmepsin2/3* and *PfMDR1* were very rare (Fig. 2). Such concomitant amplification was observed in only four isolates (4/6,722 [0.06%]): one sample from Pailin, Cambodia, collected in the year 2008 (1.58 and 1.76 *PfPlasmepsin2/3* and *PfMDR1* copies, respectively), one sample from Pursat, Cambodia, collected in 2019 (2.30 and 1.78 *PfPlasmepsin2/3* and *PfMDR1* copies, respectively), and another two from Kayin State, Myanmar (2/6,722 [0.02%]), collected in 2016 (1.51 and 1.55 *PfPlasmepsin2/3* copies and 2.08 and 2.72 *PfMDR1* copies). Application of the stricter cutoff value, corresponding to a 90% chance of a real amplification of these genes, reduced the number of samples with concomitant multiple copy numbers of *PfPlasmepsin2/3* and *PfMDR1* to three parasite samples (0.04%), collected in 2008, 2016, and 2019.




FIG 2 Distribution of *PfPlasmepsin2/3* and *PfMDR1* copy number estimates in 6,722 *P. falciparum* samples obtained from Greater Mekong subregion countries between 2007 and 2019, color-coded according to country. The shaded areas represent *PfPlasmepsin2/3* and *PfMDR1* estimates with indeterminate results, defined as a <90% chance of representing a single copy number versus multiple copy numbers of the gene.

***PfCRT* mutations in relation to *PfPlasmepsin2/3* and *PfMDR1* amplification.** A total of 536 *P. falciparum* isolates, collected between 2007 and 2019 from Cambodia ($n = 478$) and Vietnam ($n = 58$), were tested for the *PfCRT* mutations associated with piperaquine resistance. *PfCRT* mutations were found at positions T93S (12.7% [68/536]), H97Y/L (23.5% [126/536]), F145I (6.0% [32/536]), I218F (4.9% [26/536]), M343I/L (2.6% [14/536]), and G353V (5% [27/536]). In addition, the CVIET haplotype without any other *PfCRT* mutation was observed in 208/537 (38.81%) parasites; the CVIDT haplotype without other mutations was found in 47/536 (8.77%); and the CVMNK haplotype without other mutations was found in 1/536 (0.2%). Double mutations of *PfCRT* (not including the CVIET, CVIDT, and CVMNK haplotypes) were not observed, except in 13 samples with multiple clone infections (see Fig. S2 to S4 in the supplemental material).

The prevalence of novel piperaquine resistance-associated *PfCRT* mutations increased over time (Fig. 1). In 2007, 11% (5/42) of *P. falciparum* samples showed *PfPlasmepsin2/3* gene amplification, whereas no parasites had one of the novel piperaquine resistance-associated *PfCRT* mutations. After that, the prevalence of *PfPlasmepsin2/3* amplification increased to 25/100 (25.0%) in 2012 and 9/9 (100%) in 2017, together with an increase in novel *PfCRT* mutations to 16/100 (16.0%) (8 H97Y/L, 6 I218F, 1 M343I/L, and 1 G353V mutation) in 2012 and 7/9 (78%) (3 T93S, 2 H97Y/L, and 2 I218F mutations) in 2017. There was a strong association between *PfPlasmepsin2/3* amplification and the presence of the downstream *PfCRT* mutations ($r^2 = 0.89$). Of the 293 parasites carrying one of the novel *PfCRT* mutations, 216 (73.7%) also carried multiple copy numbers of *PfPlasmepsin2/3*.

Among 478 samples with complete data, we observed only a single sample (0.21% [1/478]), collected in the year 2018 from northern Cambodia, harboring a piperaquine resistance-associated *PfCRT* mutation together with amplification of *PfMDR1* (Fig. 3). This sample showed a single copy of *PfPlasmepsin2/3*. In this study, we did not identify a single sample showing a combination of all four resistance genes (amplification of *PfKelch*, *PfPlasmepsin2/3*, and *PfMDR1* and a piperaquine resistance-associated *PfCRT* mutation) (Fig. 3).

DISCUSSION

This study in the GMS analyzed the temporal trends in the prevalence of molecular markers for mefloquine resistance (*PfMDR1* amplification) and piperaquine resistance




FIG 3 Relation between *PfMDR1* amplification, *PfPlasmepsin2/3* amplification, and novel piperazine resistance-associated *PfCRT* mutations.

(*PfPlasmepsin2/3* amplification and novel piperazine resistance-associated *PfCRT* mutations). Since most resistance mechanisms result in a fitness disadvantage, the prevalence of resistant parasites and their evolution with the spread of increasingly fit lineages depend on the drug pressures on the parasite population. The results of this molecular epidemiology study thus need to be interpreted in the contexts of the use of different drugs in different countries and changes over time. Cambodia introduced ASMQ as the first-line antimalarial treatment in 2000, then changed to DHA-PPQ in 2010, and subsequently gradually changed back to ASMQ from 2014 to 2017. Vietnam deployed ASMQ until 2005 and then moved to DHA-PPQ until 2020, when four provinces changed to artesunate-pyronaridine; another two provinces did so in 2021. In Myanmar and Lao PDR, AL remains the first-line treatment, with limited use of DHA-PPQ in Myanmar. Thailand used ASMQ as its first line treatment until 2015, when it changed to DHA-PPQ. As with adjacent Cambodia, northeastern Thailand switched back to ASMQ in 2019.

In Myanmar and Lao PDR, with low levels or no drug pressure from either mefloquine or piperazine, the prevalence of parasites carrying either amplified *PfMDR1* or *PfPlasmepsin2/3* remained very low in this study. In western Thailand and Cambodia, the prevalence of multiple *PfMDR1* copy numbers increased significantly during the deployment of ASMQ and was associated with high failure rates in patients with combined artemisinin- and mefloquine-resistant infections (8). In Cambodia, the prevalence of multiple *PfMDR1* copy numbers rapidly declined after the change in first-line therapy toward DHA-PPQ in 2010. This has been confirmed in several studies (9–12) and is explained mainly by the fitness costs associated with *PfMDR1* gene amplification in the absence of mefloquine drug pressure (13). This has also been shown in *in vitro* cultures (14). In Cambodia and Vietnam, amplification of *PfPlasmepsin2/3* increased with the deployment of DHA-PPQ and increased much more rapidly in parallel with the increasingly high treatment failure rates with DHA-PPQ observed since 2013 (15, 16). In addition to *PfPlasmepsin2/3* amplification, novel mutations in the *PfCRT* gene, in addition to the chloroquine resistance-related K76T mutation (in the CVIET, CVIDT, and CVMNK haplotypes), have been associated with piperazine resistance. These novel “downstream” mutations are closely linked to, and were preceded by, amplification of *PfPlasmepsin2/3*, as shown in Fig. 1. Among patients with *P. falciparum* infections carrying multiple *PfPlasmepsin2/3* copies and one of the *PfCRT* H97Y, F145I, and G353V mutations, treatment failure rates were higher after treatment with DHA-PPQ than for infections with parasites with only *PfPlasmepsin2/3* amplified (13). The role of *PfPlasmepsin2/3* amplification in piperazine resistance is still uncertain. *Ex vivo* drug sensitivity testing of parasites with

PfPlasmepsin2/3 amplified showed increased resistance to piperazine in a bespoke piperazine survival assay (17). However, gene-edited *P. falciparum* parasites with multiple *PfPlasmepsin2/3* copies and overexpression of *PfPlasmepsin2* did not show increased piperazine resistance (18). In contrast, gene-edited parasites with *PfCRT* H97Y, F145I, M343L, or G353V mutations are resistant to piperazine *in vitro* (19). *PfPlasmepsin2/3* amplification could still play an indirect role in piperazine resistance, but this is currently unclear. The strong selective sweep of a single *PfKelch* C580Y mutation-containing *P. falciparum* lineage in the eastern GMS under DHA-PPQ drug pressure was likely initially driven by artemisinin resistance. The predominance of this lineage increased rapidly after 2009 in countries deploying DHA-PPQ, and it acquired *PfPlasmepsin2/3* amplification and, only more recently, the novel *PfCRT* mutations (20). This sequence of events is also supported by a detailed genomic epidemiological study from the same area using whole-genome sequencing, showing the initial spread of a *P. falciparum* colineage with a *PfKelch* C580Y mutation and *PfPlasmepsin2/3* amplification, which then diversified and acquired one of the novel *PfCRT* mutations (21). All studies thus far found that the novel piperazine-associated single nucleotide polymorphisms (SNPs) in *PfCRT* are mutually exclusive.

Both artemisinin resistance and piperazine resistance contributed to the high DHA-PPQ failure rates in Cambodia and Vietnam. Piperazine resistance alone is associated with recrudescence rates of approximately 20% assessed 42 days after treatment with DHA-PPQ, compared to 45% in *P. falciparum* infections with both artemisinin and piperazine resistance (12). Recrudescence resistant infections are overall more transmissible than other infections, which drives their spread (22). Artemisinin-resistant infections have high rates of gametocytemia and may be more transmissible than other infections even before treatment failure rates begin to rise (23). After the withdrawal of DHA-PPQ in Cambodia in 2016, the prevalence of parasites with *PfPlasmepsin2/3* amplified declined from close to 100% to 38%, but these parasites have not disappeared, in contrast with the complete disappearance of *PfMDR1* amplification after mefloquine withdrawal. This may suggest either a lower fitness cost for parasites carrying multiple *PfPlasmepsin2/3* copy numbers or some other, unidentified advantage not associated with piperazine resistance. The relative fitness of *P. falciparum* parasites carrying multiple copies of *PfPlasmepsin* or the novel *PfCRT* mutations has not been established. Alternatively, the currently very low level of multiplicity of malaria infection may allow relatively unfit parasites to persist in the absence of competition. Concomitant *PfMDR1* amplification and *PfCRT* mutations associated with piperazine resistance were not observed, except in one parasite strain with a single *PfPlasmepsin2/3* copy number. Parasites carrying both an amplified *PfMDR1* gene and an amplified *PfPlasmepsin2/3* gene were also very rare; only single cases were observed in 2008, 2016, and 2019, for an overall prevalence of 0.06% (4/6,722), or 0.04% (3/6,722) when the stricter cutoff value is applied. Assuming free mixing between parasite populations, a rough estimate of the total expected parasite strains with both the *PfPlasmepsin2/3* and *PfMDR1* genes amplified would be around 17, a number obtained by simply multiplying the proportions of each amplified gene by year and the total number of parasite samples assessed per year. Also, in Cambodia between 2014 and 2016, when both ASMQ and DHA-PPQ were deployed, not a single parasite carrying amplification of both genes was observed. The observations suggest that amplification of both genes in the same *P. falciparum* parasite may confer a fitness disadvantage or compromised transmissibility. Interestingly, the increase in *PfMDR1* gene amplification in Cambodia after the redeployment of ASMQ has been less pronounced than in the first decade of the millennium, when deployment of this ACT in Cambodia followed nearly 2 decades of mefloquine monotherapy in adjacent Thailand. Despite the increasing use of ASMQ since 2014, with full deployment since 2017, the prevalence of parasites with multiple *PfMDR1* copies increased to only 8% (12/160) in 2019, and ASMQ remains to date an effective treatment for uncomplicated falciparum malaria in Cambodia (3). The much lower levels of transmission, and thus the lower level of competition, may again be a contributor. It may also be that amplification of both *PfMDR1* and *PfPlasmepsin2/3* within the same parasite renders the

parasite very unfit. The continued relatively high prevalence of *PfPlasmepps* amplification would then be a barrier to a rapid increase in *PfMDR1* amplification and thus to the reemergence of mefloquine resistance.

These data support the continued deployment of ASMQ in Cambodia. The very low prevalence of concomitant mefloquine and piperazine resistance also supports the strategy of combining both drugs in triple artemisinin combination therapies (TACT), in which an artemisinin derivative is combined with two well-matched existing partner drugs (5). This provides a more effective treatment for multidrug-resistant falciparum malaria but could also extend the life span of existing antimalarial drugs by slowing or preventing the emergence of resistance. The TACT DHA-PPQ plus MQ was recently studied in a large randomized trial in uncomplicated falciparum malaria (24). This TACT was shown to be well tolerated, safe, and highly effective, including in areas of multidrug-resistant malaria such as Cambodia and Vietnam. TACT could therefore be one of the few remaining treatment options in the GMS. However, sustained efficacy will depend on the absence of fit parasites which are resistant to both partner drugs, since these parasites would be readily selected with the deployment of a TACT containing DHA-PPQ plus MQ.

Other studies confirm the absence of concomitant *PfPlasmepps*2/3 and *PfMDR1* amplification (19, 25). However, a retrospective study in Cambodia in 2017 reported a much higher prevalence than in this study; as many as 30% of parasites had amplification of both *PfMDR1* and *PfPlasmepps*2/3, although this was not associated with increased rates of treatment failure with ASMQ (26). We believe that the different methodology used to assess gene copy numbers in this study, dye-based quantitative PCR (qPCR) assays, might have resulted in substantial overestimation of gene amplifications. Although dye-based qPCR assays, including those with EvaGreen and SYBR green, have certain advantages over probe-based qPCR assays in terms of cost-effectiveness and time efficiency, these dyes can bind nonspecifically to double-stranded DNA outside the targeted qPCR product. This causes increased background signal and false-positive results (27). In the current study, in parasites with a copy number readout above 1.52, the statistically determined cutoff for a >90% chance of genuine *PfPlasmepps*2/3 amplification, the proportion of parasites carrying the characteristic SNP at the duplication breakpoint for *PfPlasmepps*2/3 was 88%. This confirms the reliability of our results but also shows that in a minority (around 10%) of parasite samples, *PfPlasmepps*2/3 amplification might have been assigned wrongly.

A shortcoming of our study is that gene amplification in a minor *P. falciparum* clone in patients with multiple clone infections might not have been detected by using the current cutoff for the estimated copy number. This cannot be a large confounder, since multiple clone infections were identified in only 263 of 2,710 samples (9.7%). Another caveat is that the absence of *PfMDR1* amplification might not exclude mefloquine resistance, since the drug is thought to have several targets (28). In earlier studies of mefloquine resistance in Thailand, *PfMDR1* amplification accounted for only two-thirds of the variance in susceptibility (13). Concomitant resistance to piperazine and mefloquine might then not be detected by the current resistance markers. This emphasizes the importance of continuing to test *in vitro* drug susceptibility—particularly in treatment failures.

In conclusion, our study shows that the molecular genetic markers for mefloquine and piperazine resistance have evolved differently in the western and eastern GMS. This appears to have resulted from the differences in antimalarial drug pressure. In contrast to the disappearance of *PfMDR1* amplification after the discontinuation of ASMQ, the prevalence of *PfPlasmepps*2/3 amplification in Cambodia remains high after the discontinuation of DHA-piperazine. Concomitant amplification of *PfMDR1* and *PfPlasmepps*2/3 in the same *P. falciparum* parasite, as well as simultaneous occurrence of the novel *PfCRT* mutations and *PfMDR1* amplification, is extremely rare. Mechanisms conferring mefloquine and piperazine resistance may counteract each other. This can be evaluated in the laboratory with gene-edited *P. falciparum* strains and through

continued genetic epidemiological surveillance. These results provide support for the development and evaluation of a TACT containing artesunate, mefloquine, and piperazine.

MATERIALS AND METHODS

Sample collection and processing. As part of studies on the treatment, epidemiology, and targeted elimination of artemisinin-resistant malaria (ClinicalTrials registration no. NCT01350856, NCT02453308, NCT03384498, NCT03355664, and NCT01872702), venous blood samples, filter paper blood spots, and completed rapid diagnostic test strips were collected from patients with microscopy- or rapid-test-confirmed uncomplicated falciparum malaria, as well as from healthy individuals in villages where targeted malaria elimination activities were planned. The study sites in Myanmar, Thailand, Cambodia, Lao PDR, and Vietnam were subjects of large multinational observational and treatment studies in patients with falciparum malaria (TRAC I and TRAC II), or of large-scale malaria prevalence surveillance as part of malaria elimination studies. Full details of these clinical and epidemiological studies have been published previously, and some of the raw data used for this study is included in these publications (9, 20, 23, 24, 29, 30). Approvals for the studies were obtained from the Ethical Review Boards of the Faculty of Tropical Medicine, Mahidol University (MUTM 2017-045-03, MUTM 2011-015-01) and the University of Oxford Tropical Medicine Ethics Committee (protocols 527-17, 06-11, 1017-13, 1015-13, 32-17), the Department of Medical Research, Ministry of Health (Myanmar), the Lao National Ethics Committee for Health Research, and the National Ethical Committee for Health Research in Cambodia.

DNA was extracted from dried blood spots, completed rapid diagnostic test strips (both stored desiccated at room temperature), and frozen whole-blood samples by standard methods at the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. DNA was purified using a Qiagen kit (Qiagen, Germany) according to the manufacturer's instructions.

Assessment of mutations in *PfKelch* and *PfCRT*. Polymorphisms in the *PfKelch* gene were examined by nested PCR amplification covering the propeller region of the gene as described previously (23), followed by sequencing of the gene using an ABI sequencer (Macrogen Inc, South Korea). The sequencing results were then aligned against the *PfKelch* gene (PF13_0238) of the reference strain 3D7 (NCBI reference sequence no. [XM_001350122.1](#)). Analysis was performed with BioEdit software (Abbott, CA, USA).

PfCRT was amplified from the DNA template using nested PCR. A PCR-restriction fragment length polymorphism assay was developed to assess *PfCRT* mutations related to piperazine resistance identified in a previous study (19). These included the following single nucleotide polymorphisms (SNPs): N88K, T93S, H97Y, F145I, I218F, CVMNK72–76CVIET, N326S, M343L, G353V, I356T, and R371I. Digestion fragments were analyzed on a 3% agarose gel. For quality control, a random one-third of all PCR products were sent for DNA sequencing at Macrogen Inc, South Korea.

Assessment of *PfPlasmepps*2/3 and *PfMDR1* gene amplification. *PfPlasmepps*2/3 and *PfMDR1* copy numbers were quantified using relative quantitative real-time PCR (TaqMan real-time PCR) on a Corbett Rotor-Gene Q system (Corbett Research, Australia). The primers and probes have been described previously (10, 13). Amplification was performed in triplicate on a total volume of 10 μ l as multiplex PCR using a QuantiTect Multiplex PCR NoROX kit (Qiagen, Germany). Copy number estimates were calculated as $2^{-\Delta\Delta C_T}$, where $\Delta\Delta C_T$ denotes the difference between the change in the threshold cycle (ΔC_T) of the unknown sample and the ΔC_T of the reference sample. Reactions were repeated whenever the profile did not conform to exponential kinetics, or if the standard deviation of the $\Delta\Delta C_T$ values was >1.5 or the C_T value of the PCR was >35 . To confirm amplification and to resolve indeterminate results, samples passing these criteria but with an estimated copy number of >1.3 were also retested once, and the last result counted as final. For the main analysis, a cutoff copy number estimate of 1.5 was used to distinguish single- from multiple-copy *PfPlasmepps*2/3 and *PfMDR1* gene carriage, as used in previous studies (31–33). In addition, we defined the cutoffs for the 90% probabilities that the copy number estimate denotes a single copy number rather than multiple copy numbers of the gene. These probabilities were based on the distributions of the results obtained by the formula calculating the estimated copy number (see Fig. S1 in the supplemental material). This approach acknowledges that values around the cutoff will include the tail ends of the distributions of copy number estimate values representing *P. falciparum* samples carrying one versus two copies of the *PfPlasmepps*2/3 or *PfMDR1* gene. For this assessment of adapted cutoff values, samples carrying multiple *P. falciparum* clones were excluded. Using this approach, values between 1.14 and 1.52 for *PfPlasmepps*2/3 and values between 1.15 and 1.61 for *PfMDR1* were considered indeterminate, i.e., the distinction of single from multiple copy numbers of the gene was uncertain (Fig. S1). For 2,710 samples, *PfPlasmepps*2/3 amplification was also assessed by genotyping the SNP characteristic of the duplication breakpoint (34). Among parasites with a copy number estimate above the 90% probability cutoff of 1.52, *PfPlasmepps*2/3 amplification was confirmed in 595/675 (88%) using this alternative method. For estimates of <1.14 , the 90% probability cutoff for a single gene copy number, and for indeterminate values between 1.14 and 1.52, the proportions of parasites with *PfPlasmepps*2/3 amplified according to the presence of the breakpoint SNP were 75/1,734 (4%) and 114/301 (38%), respectively.

Availability of data and materials. All data generated or analyzed during this study are included in this published article and its supplemental material files.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.5 MB.

ACKNOWLEDGMENTS

This study was supported by Mahidol University, Thailand Science Research and Innovation (TSRI) (award RTA6280006), and Initiative 5%, Expertise France. Some patient samples were from TRAC studies supported by the United Kingdom Foreign Commonwealth Development Office (FCDO) (program code 201900); other samples from healthy individuals were from studies of targeted malaria elimination funded by the Wellcome Trust (grant 101148/Z/13/Z) and the Bill and Melinda Gates Foundation (grant OPP1081420). These studies were part of the Mahidol University–Oxford Tropical Medicine Research Program, funded by the Wellcome Trust of the United Kingdom (core grant 106698/B/14/Z). For the purpose of open access, the authors have applied a CC BY public copyright license to any author accepted manuscript version arising from this submission.

M.I., N.J.W., and A.M.D. contributed to the study design. R.V., C.P., A.S., A.P.P., S.P., T.P., C.N., O.M., R.T., N.H.C., D.L., H.D.T.N., T.J.P., J.J.C., R.W.V.D.P., C.A., L.V.S., M. Mayxay, N.T.T.-N., P.N.N., N.P.J.P., E.A.A., F.H.N., F.M.S., M.D., and A.M.D. collected clinical samples and data. K.S., S.S., and M.I. prepared DNA and genotyped and sequenced it. M.I., K.S., M. Mukaka, N.J.W., and A.M.D. analyzed the data. M.I., N.J.W., and A.M.D. wrote the report. All authors read and approved the final manuscript.

We declare no competing financial interests.

REFERENCES

- World Health Organization. 2020. World malaria report 2020: 20 years of global progress and challenges. World Health Organization, Geneva, Switzerland. <https://www.who.int/publications/i/item/9789240015791>.
- Medicines for Malaria Venture. Malaria and medicines. <https://www.mmv.org/malaria-medicines>.
- World Health Organization. 2020. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). World Health Organization, Geneva, Switzerland. <https://www.who.int/publications/i/item/9789240012813>.
- Mathieu LC, Cox H, Early AM, Mok S, Lazrek Y, Paquet JC, Ade MP, Lucchi NW, Grant Q, Udhayakumar V, Alexandre JS, Demar M, Ringwald P, Neafsey DE, Fidock DA, Musset L. 2020. Local emergence in Amazonia of *Plasmodium falciparum* k13 C580Y mutants associated with in vitro artemisinin resistance. *Elife* 9:e51015. <https://doi.org/10.7554/eLife.51015>.
- van der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. 2021. Triple artemisinin-based combination therapies for malaria—a new paradigm? *Trends Parasitol* 37:15–24. <https://doi.org/10.1016/j.pt.2020.09.011>.
- Basco LK, Eldin de Pécoules P, Wilson CM, Le Bras J, Mazabraud A. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in *Plasmodium falciparum*. *Mol Biochem Parasitol* 69:135–138. [https://doi.org/10.1016/0166-6851\(94\)00207-4](https://doi.org/10.1016/0166-6851(94)00207-4).
- Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, Habimana RM, Rucogoza A, Moriarty LF, Sandford R, Piercefield E, Goldman I, Ezema B, Talundzic E, Pacheco MA, Escalante AA, Ngamije D, Mangala JN, Kabera M, Munguti K, Murindahabi M, Brieger W, Musanabaganwa C, Mutesa L, Udhayakumar V, Mbituyumuremyi A, Halsey ES, Lucchi NW. 2021. Association of *Plasmodium falciparum* kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. *Lancet Infect Dis* 21:1120–1128. [https://doi.org/10.1016/S1473-3099\(21\)00142-0](https://doi.org/10.1016/S1473-3099(21)00142-0).
- Phyo AP, Ashley EA, Anderson TJ, Bozdech Z, Carrara VI, Sriprawat K, Nair S, White MM, Dziekan J, Ling C, Proux S, Konghahong K, Jeeyapant A, Woodrow CJ, Imwong M, McGready R, Lwin KM, Day NPJ, White NJ, Nosten F. 2016. Declining efficacy of artemisinin combination therapy against *P. falciparum* malaria on the Thai-Myanmar border (2003–2013): the role of parasite genetic factors. *Clin Infect Dis* 63:784–791. <https://doi.org/10.1093/cid/ciw388>.
- Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, Suwannasin K, Kunasol C, Srisutham S, Duanguppama J, Vongprommek R, Promnarate C, Saejeng A, Khantikul N, Sugaram R, Thanapongpichat S, Sawangjaroen N, Sutawong K, Han KT, Htut Y, Linn K, Win AA, Hlaing TM, van der Pluijm RW, Mayxay M, Pongvongsa T, Phommason K, Tripura R, Peto TJ, von Seidlein L, Nguon C, Lek D, Chan XHS, Rekol H, Leang R, Huch C, Kwiatkowski DP, Miotto O, Ashley EA, Kyaw MP, Pukrittayakamee S, Day NPJ, Dondorp AM, Smithuis FM, Nosten FH, White NJ. 2020. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. *Lancet Infect Dis* 20:1470–1480. [https://doi.org/10.1016/S1473-3099\(20\)30228-0](https://doi.org/10.1016/S1473-3099(20)30228-0).
- Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almagro-Garcia J, Neal AT, Sreng S, Suon S, Drury E, Jyothi D, Stalker J, Kwiatkowski DP, Fairhurst RM. 2017. Genetic markers associated with dihydroartemisinin-piperaquine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype-phenotype association study. *Lancet Infect Dis* 17:164–173. [https://doi.org/10.1016/S1473-3099\(16\)30409-1](https://doi.org/10.1016/S1473-3099(16)30409-1).
- Parobek CM, Parr JB, Brazeau NF, Lon C, Chaorattanakawee S, Gosi P, Barnett EJ, Norris LD, Meshnick SR, Spring MD, Lanteri CA, Bailey JA, Saunders DL, Lin JT, Juliano JJ. 2017. Partner-drug resistance and population substructuring of artemisinin-resistant *Plasmodium falciparum* in Cambodia. *Genome Biol Evol* 9:1673–1686. <https://doi.org/10.1093/gbe/evx126>.
- Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeung N, Eam R, Khean C, Ken M, Loch K, Bouillon A, Domergue A, Ma L, Bouchier C, Leang R, Huy R, Nuel G, Barale JC, Legrand E, Ringwald P, Fidock DA, Mercereau-Puijalon O, Ariey F, Ménard D. 2017. A surrogate marker of piperaquine-resistant *Plasmodium falciparum* malaria: a phenotype-genotype association study. *Lancet Infect Dis* 17:174–183. [https://doi.org/10.1016/S1473-3099\(16\)30415-7](https://doi.org/10.1016/S1473-3099(16)30415-7).
- Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S. 2004. Mefloquine resistance in *Plasmodium falciparum* and increased pfmdr1 gene copy number. *Lancet* 364:438–447. [https://doi.org/10.1016/S0140-6736\(04\)16767-6](https://doi.org/10.1016/S0140-6736(04)16767-6).
- Preechapornkul P, Imwong M, Chotivanich K, Pongtavornpinyo W, Dondorp AM, Day NP, White NJ, Pukrittayakamee S. 2009. *Plasmodium falciparum* pfmdr1 amplification, mefloquine resistance, and parasite fitness. *Antimicrob Agents Chemother* 53:1509–1515. <https://doi.org/10.1128/AAC.00241-08>.
- Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM. 2016. Dihydroartemisinin-piperaquine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet Infect Dis* 16:357–365. [https://doi.org/10.1016/S1473-3099\(15\)00487-9](https://doi.org/10.1016/S1473-3099(15)00487-9).
- Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, Ménard D, Tarning J, Bustos D, Ringwald P, Galappaththy GL, Thieu NQ. 2017. Treatment failure of dihydroartemisinin/piperaquine for *Plasmodium falciparum* malaria, Vietnam. *Emerg Infect Dis* 23:715–717. <https://doi.org/10.3201/eid2304.161872>.
- Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, Ke S, Chy S, Eam R, Khean C, Loch K, Ken M, Lek D, Beghain J, Ariey F, Guerin PJ, Huy R, Mercereau-Puijalon O, Witkowski B, Ménard D. 2015. *Plasmodium falciparum* dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel

- piperazine in vitro assays: retrospective and prospective investigations. *BMC Med* 13:305. <https://doi.org/10.1186/s12916-015-0539-5>.
18. Loesbanluechai D, Kotanan N, de Cozar C, Kochakarn T, Ansbro MR, Chotivanich K, White NJ, Wilairat P, Lee MCS, Gamo FJ, Sanz LM, Chookajorn T, Kumpornsin K. 2019. Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in *Plasmodium falciparum* sensitivity to artesunate, chloroquine and piperazine. *Int J Parasitol Drugs Drug Resist* 9:16–22. <https://doi.org/10.1016/j.ijpddr.2018.11.004>.
 19. Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, Takala-Harrison S, Witkowski B, Fairhurst RM, Arie F, Menard D, Fidock DA. 2018. Emerging Southeast Asian PfCRT mutations confer *Plasmodium falciparum* resistance to the first-line antimalarial piperazine. *Nat Commun* 9:3314. <https://doi.org/10.1038/s41467-018-05652-0>.
 20. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van der Pluijm RW, Tripura R, Miotto O, Menard D, Dhorda M, Day NPJ, White NJ, Dondorp AM. 2017. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiology observational study. *Lancet Infect Dis* 17:491–497. [https://doi.org/10.1016/S1473-3099\(17\)30048-8](https://doi.org/10.1016/S1473-3099(17)30048-8).
 21. Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, Hien TT, Hongvanthong B, Chindavongsa K, Mayxay M, Huy R, Leang R, Huch C, Dysoley L, Amaratunga C, Suon S, Fairhurst RM, Tripura R, Peto TJ, Sovann Y, Jittamala P, Hanboonkunupakarn B, Pukrittayakamee S, Chau NH, Imwong M, Dhorda M, Vongpromek R, Chan XHS, Maude RJ, Pearson RD, Nguyen T, Rockett K, Drury E, Gonçalves S, White NJ, Day NP, Kwiatkowski DP, Dondorp AM, Miotto O. 2019. Evolution and expansion of multidrug-resistant malaria in Southeast Asia: a genomic epidemiology study. *Lancet Infect Dis* 19:943–951. [https://doi.org/10.1016/S1473-3099\(19\)30392-5](https://doi.org/10.1016/S1473-3099(19)30392-5).
 22. Price R, Nosten F, Simpson JA, Luxemburger C, Phaipun L, ter Kuile F, van Vugt M, Chongsuphajaisiddhi T, White NJ. 1999. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. *Am J Trop Med Hyg* 60:1019–1023. <https://doi.org/10.4269/ajtmh.1999.60.1019>.
 23. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaro S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Tracking Resistance to Artemisinin Collaboration (TRAC), et al. 2014. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 371:411–423. <https://doi.org/10.1056/NEJMoa1314981>.
 24. van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, Ul Islam A, Anvikar AR, Satpathi P, Satpathi S, Behera PK, Tripura A, Baidya S, Onyamboko M, Chau NH, Sovann Y, Suon S, Sreng S, Mao S, Oun S, Yen S, Amaratunga C, Chutasmit K, Saelow C, Runcharern R, Kaewmok W, Hoa NT, Thanh NV, Hanboonkunupakarn B, Callery JJ, Mohanty AK, Heaton J, Thant M, Gantait K, Ghosh T, Amato R, Pearson RD, Jacob CG, Gonçalves S, Mukaka M, Waithira N, Woodrow CJ, Grobusch MP, van Vugt M, Fairhurst RM, Cheah PY, Peto TJ, von Seidlein L, Dhorda M, Maude RJ, Winterberg M, et al. 2020. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated *Plasmodium falciparum* malaria: a multicentre, open-label, randomised clinical trial. *Lancet* 395:1345–1360. [https://doi.org/10.1016/S0140-6736\(20\)30552-3](https://doi.org/10.1016/S0140-6736(20)30552-3).
 25. van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, Jittamala P, Hanboonkunupakarn B, Chutasmit K, Saelow C, Runjarern R, Kaewmok W, Tripura R, Peto TJ, Yok S, Suon S, Sreng S, Mao S, Oun S, Yen S, Amaratunga C, Lek D, Huy R, Dhorda M, Chotivanich K, Ashley EA, Mukaka M, Waithira N, Cheah PY, Maude RJ, Amato R, Pearson RD, Gonçalves S, Jacob CG, Hamilton WL, Fairhurst RM, Tarning J, Winterberg M, Kwiatkowski DP, Pukrittayakamee S, Hien TT, Day NP, Miotto O, White NJ, Dondorp AM. 2019. Determinants of dihydroartemisinin-piperazine treatment failure in *Plasmodium falciparum* malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. *Lancet Infect Dis* 19:952–961. [https://doi.org/10.1016/S1473-3099\(19\)30391-3](https://doi.org/10.1016/S1473-3099(19)30391-3).
 26. Rossi G, De Smet M, Khim N, Kindermans JM, Menard D. 2017. Emergence of *Plasmodium falciparum* triple mutant in Cambodia. *Lancet Infect Dis* 17:1233. [https://doi.org/10.1016/S1473-3099\(17\)30635-7](https://doi.org/10.1016/S1473-3099(17)30635-7).
 27. Ruiz-Villalba A, van Pelt-Verkuil E, Gunst QD, Ruijter JM, van den Hoff MJ. 2017. Amplification of nonspecific products in quantitative polymerase chain reactions (qPCR). *Biomol Detect Quantif* 14:7–18. <https://doi.org/10.1016/j.bdq.2017.10.001>.
 28. Wong W, Bai XC, Sleebs BE, Trigila T, Brown A, Thompson JK, Jackson KE, Hanssen E, Marapana DS, Fernandez IS, Ralph SA, Cowman AF, Scheres SHW, Baum J. 2017. Mefloquine targets the *Plasmodium falciparum* 80S ribosome to inhibit protein synthesis. *Nat Microbiol* 2:17031. <https://doi.org/10.1038/nmicrobiol.2017.31>.
 29. Landier J, Parker DM, Thu AM, Lwin KM, Delmas G, Nosten FH, Malaria Elimination Task Force Group. 2018. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on *Plasmodium falciparum* malaria in Eastern Myanmar: an observational study of a regional elimination programme. *Lancet* 391:1916–1926. [https://doi.org/10.1016/S0140-6736\(18\)30792-X](https://doi.org/10.1016/S0140-6736(18)30792-X).
 30. von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, Pongvongsa T, Lwin KM, Keerecharoen L, Kajechiwa L, Thwin MM, Parker DM, Wiladphaingern J, Nosten S, Proux S, Corbel V, Tuong-Vy N, Phuc-Nhi TL, Son DH, Huong-Thu PN, Tuyen NTK, Tien NT, Dong LT, Hue DV, Quang HH, Nguon C, Davoeung C, Rekol H, Adhikari B, Henriques G, Phongmany P, Suangkanarat P, Jeeyapant A, Vihokhern B, van der Pluijm RW, Lubell Y, White LJ, Aguas R, Promnarate C, Sirthiranont P, Malleret B, Rénia L, Onsjö C, Chan XH, Chalk J, Miotto O, Patumrat K, Chotivanich K, Hanboonkunupakarn B, Jittamala P, et al. 2019. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial. *PLoS Med* 16:e1002745. <https://doi.org/10.1371/journal.pmed.1002745>.
 31. Ansbro MR, Jacob CG, Amato R, Kekre M, Amaratunga C, Sreng S, Suon S, Miotto O, Fairhurst RM, Welles TE, Kwiatkowski DP. 2020. Development of copy number assays for detection and surveillance of piperazine resistance associated plasmepsin 2/3 copy number variation in *Plasmodium falciparum*. *Malar J* 19:181. <https://doi.org/10.1186/s12936-020-03249-x>.
 32. Costa GL, Amaral LC, Fontes CJF, Carvalho LH, de Brito CFA, de Sousa TN. 2017. Assessment of copy number variation in genes related to drug resistance in *Plasmodium vivax* and *Plasmodium falciparum* isolates from the Brazilian Amazon and a systematic review of the literature. *Malar J* 16:152. <https://doi.org/10.1186/s12936-017-1806-z>.
 33. Ionita-Laza I, Rogers AJ, Lange C, Raby BA, Lee C. 2009. Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. *Genomics* 93:22–26. <https://doi.org/10.1016/j.ygeno.2008.08.012>.
 34. Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, Sreng S, Drury E, Stalker J, Miotto O, Fairhurst RM, Kwiatkowski DP. 2018. Origins of the current outbreak of multidrug-resistant malaria in Southeast Asia: a retrospective genetic study. *Lancet Infect Dis* 18:337–345. [https://doi.org/10.1016/S1473-3099\(18\)30068-9](https://doi.org/10.1016/S1473-3099(18)30068-9).